Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 7:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 77 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Glycine Clear all
Completed Phase 2 Interventional

Glycine to Treat Psychotic Disorders in Children

NCT00005658
View directory record Official record
Conditions
Psychotic Disorder, Schizoaffecitve Disorder, Schizophrenia
Interventions
Glycine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 16, 2026, 7:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls

NCT01461109
View directory record Official record
Conditions
Parkinson Disease, Alzheimer Disease
Interventions
[18F] CFPyPB
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 16, 2026, 7:57 PM EDT
Completed Not applicable Interventional

Adjunctive Glycine for Obsessive Compulsive Disorder

NCT00405535
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
glycine, placebo
Drug · Other
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 16, 2026, 7:57 PM EDT
Terminated Early Phase 1 Interventional

Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19

NCT04703036
View directory record Official record
Conditions
Covid19
Interventions
Glycine, N-acetylcysteine, Alanine
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
55 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 16, 2026, 7:57 PM EDT
Completed Phase 1Phase 2 Interventional

Project 2 Airway Potential Hydrogen (pH) in Asthma

NCT03617718
View directory record Official record
Conditions
Cystic Fibrosis, Asthma, Severe Persistent Asthma, Healthy
Interventions
Glycine Buffer
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 50 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 16, 2026, 7:57 PM EDT
Withdrawn Phase 3 Interventional

Glycine and D-Cycloserine in Schizophrenia

NCT00000372
View directory record Official record
Conditions
Schizophrenia
Interventions
D-cycloserine, Glycine, Clozapine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Oct 16, 2026, 7:57 PM EDT
Terminated Phase 1 Interventional

Study of the Effects of Glycine on Symptoms and Memory in Patients With Schizophrenia

NCT00575848
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Glycine, Placebo
Dietary Supplement
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2009 · Synced Oct 16, 2026, 7:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparing Blood Sugar Levels and Endothelial Function of PEAK ATP® With GlycoCarn®, PEAK ATP® and GlycoCarn® Supplements

NCT01855373
View directory record Official record
Conditions
Blood Sugar, Endothelial Function
Interventions
PEAK ATP® with GlycoCarn®, PEAK ATP®, GlycoCarn®, Placebo
Dietary Supplement · Other
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 16, 2026, 7:57 PM EDT
Terminated Phase 2 Interventional Results available

A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis

NCT00913692
View directory record Official record
Conditions
Herpes Labialis, Herpes Simplex Virus
Interventions
Glutamine, Glycine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 16, 2026, 7:57 PM EDT
Completed Phase 4 Interventional Results available

Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria

NCT02125721
View directory record Official record
Conditions
Cystinuria
Interventions
Tiopronin 1g per day, Tiopronin 2g per day, Tiopronin 3g per day
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 16, 2026, 7:57 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Brown Adipose Tissue Pilot

NCT03793127
View directory record Official record
Conditions
Aging
Interventions
Maximal oxygen consumption (V02 max), Brown adipose tissue (BAT) imaging, Muscle function testing
Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
20 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 16, 2026, 7:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Poweroff Sleep Study

NCT03364101
View directory record Official record
Conditions
Sleep
Interventions
Placebo Capsule, POWEROFF Capsule
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 16, 2026, 7:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers

NCT02366364
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, NRX-1074 375 mg, NRX-1074 500 mg, NRX-1074 750 mg
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 16, 2026, 7:57 PM EDT
Completed Phase 3 Interventional Results available

Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT00220740
View directory record Official record
Conditions
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
6
States / cities
New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 16, 2026, 7:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pharmacokinetic Profile of N-Acetyl Cysteine

NCT06252519
View directory record Official record
Conditions
Pharmacokinetics
Interventions
NAC, Neuro-NAC, Neuro-NAC XS
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 16, 2026, 7:57 PM EDT
Recruiting Early Phase 1 Interventional

Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression

NCT07560878
View directory record Official record
Conditions
Major Depression
Interventions
D-Cycloserine (DCS), Continuous theta-burst stimulation (cTBS), Transcranial Magnetic Stimulation Sham, Memantine, Lorazepam (drug), Baclofen, Placebo
Drug · Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 16, 2026, 7:57 PM EDT
Active, not recruiting Early Phase 1 Interventional

Glutathione in Mild Cognitive Impairment

NCT03493178
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Glycine, N-acetylcysteine (NAC), Alanine
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
55 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 16, 2026, 7:57 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking

NCT00218465
View directory record Official record
Conditions
Nicotine Dependence
Interventions
GW468816, Placebo Comparator: Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 16, 2026, 7:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute Glycine Pharmacodynamic Study

NCT01610011
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Glycine administration
Dietary Supplement
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 16, 2026, 7:57 PM EDT
Recruiting Phase 4 Interventional

Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplasty

NCT06083480
View directory record Official record
Conditions
Osteoarthritis, Knee, Total Knee Arthroplasty, Chronic Postsurgical Pain
Interventions
GlyNAC (combination of glycine and n-acetylcysteine), Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 16, 2026, 7:57 PM EDT
Completed Phase 2 Interventional

Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder

NCT02067793
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NRX-1074 1 mg, Placebo, NRX-1074 5 mg, NRX-1074 10 mg
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Oakland, California • Skokie, Illinois • Wichita, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 16, 2026, 7:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Supplement and Acute Resistance Exercise

NCT06801951
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
acute resistance exercise with oral nutrition supplementation, stable tracer infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 16, 2026, 7:57 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.

NCT00929370
View directory record Official record
Conditions
Schizophrenia
Interventions
Glycine Transporter-1 inhibitor
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Glendale, California • Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2009 · Synced Oct 16, 2026, 7:57 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of D-serine in Schizophrenia

NCT00322023
View directory record Official record
Conditions
Schizophrenia
Interventions
D-serine
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
New Haven, Connecticut • Glen Oaks, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 16, 2026, 7:57 PM EDT